Technologies

Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more.

The Plastic Degradation project identifies microbes from natural sources that have a low-level ability to degrade multiple types of plastic. In the laboratory, with the help of synthetic biology, those microbes then are evolved into much more effective plastic-eating microbes that, in the future, could be globally deployed to decompose plastic waste.

WurQ combines wearable sensors, with deep learning and signal processing algorithms, to assess the amount, quality, and intensity of functional movements and strength training activities. This quantitative data enables feedback, guidance, and gamification at scale to improve users fitness routines and health.

EnPlusOne Biosciences is enabling RNA oligonucleotide manufacturing at scale, meeting the increasing demand for RNA drugs with an enzymatic process that is more efficient and creates a smaller environmental footprint.

Project 1985 is commercializing the Wyss Institute’s Pop-Up MEMS technology to quickly and cheaply develop tiny robotic tools for minimally invasive surgery.

Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.